Company Overview
Exagen Inc. operates within the healthcare sector, specifically focusing on the diagnostics and research industry, where it designs, develops, and commercializes testing products under the AVISE brand to assist healthcare providers in the diagnosis, prognosis, and monitoring of complex rheumatic, autoimmune, and related diseases. The company maintains a workforce of 216 employees and holds a total market capitalization of $64.46M, reflecting its status as a mid-sized entity within the specialized medical technology space. Its annual revenue over the trailing twelve months reached $66.58M, indicating a significant operational scale despite the absence of profitability in recent periods. The market cap figure of $64.46M relative to its revenue stream suggests that the market is pricing the stock based on future potential and intellectual property value rather than current earnings power, as the company is still in a phase where revenue generation is prioritized over immediate profit realization.
Financial Health
The company reported a revenue of $66.58M for the trailing twelve months, yet it posted a net income of $-19,951,000 and an EBITDA of $-11,952,000, revealing a substantial gap between top-line growth and bottom-line performance that highlights a cost structure where operating expenses significantly outpace gross profit generation. This negative free cash flow of $-10,364,500 indicates that the company is currently burning cash to fund its operations and product development, which limits immediate financial flexibility but is a common characteristic for firms in high-growth, capital-intensive research phases. The gross margin stands at 58.3%, suggesting that the core diagnostic products retain favorable pricing power relative to the cost of goods sold, while the operating margin of -29.9% and profit margin of -30.0% demonstrate that high overhead costs, likely related to R&D and commercialization efforts, are eroding profitability. On the balance sheet, the company holds $32.22M in cash against $27.67M in debt, creating a net cash position, yet the debt-to-equity ratio of 158.55 indicates a highly leveraged capital structure relative to its shareholders' equity. Despite the leverage, a current ratio of 3.45 suggests strong short-term liquidity, as the company possesses more than three times the current assets needed to cover its current liabilities. Finally, the return on equity of -147.8% and return on assets of -17.1% reveal that management has not yet achieved positive returns on the capital invested, reflecting the transitional nature of the business before it reaches a profitable maturity stage.
Valuation Assessment
The trailing twelve-month P/E ratio is listed as N/A due to the lack of positive earnings, while the forward P/E is -8.65, implying that the market expects earnings to remain negative in the near term or that valuation models are relying on alternative metrics due to the lack of profitability. The price-to-book ratio is 3.52, which indicates that the market values the company at a significant premium over its tangible book value, suggesting high expectations for the future monetization of its intellectual property and testing platform. When using alternative valuation metrics, the price-to-sales ratio of 0.97 and EV/EBITDA of -5.01 provide a clearer picture of the company's worth relative to its sales, indicating that investors are willing to pay nearly one dollar for every dollar of revenue generated. The stock has seen significant price volatility, with a 52-week high of $12.23 and a 52-week low of $2.63, placing the current trading price somewhere within this wide range and highlighting the speculative nature of the investment. The beta value of 1.91 indicates that the stock is nearly twice as volatile as the broader market, meaning that price movements in XGN will likely be amplified relative to general market shifts.
Growth & Income
Exagen Inc. demonstrated robust revenue growth of 21.8% year-over-year, while earnings growth is listed as N/A due to the company's continued losses, implying that top-line expansion is occurring faster than the path to profitability, which is typical for companies scaling commercial operations in specialized medical fields. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available cash flow is being reinvested back into the business to fund research, development, and market expansion rather than being distributed to shareholders. Consequently, the overall growth and income profile is characterized by aggressive revenue expansion without income distribution, relying entirely on future profitability to support shareholder value creation. This reinvestment strategy suggests that the company is prioritizing long-term market penetration and product development over providing immediate income returns to investors.